Spots Global Cancer Trial Database for tislelizumab combined with lenvatinib
Every month we try and update this database with for tislelizumab combined with lenvatinib cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | NCT04834986 | Resectable Hepa... | Tislelizumab co... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | NCT04834986 | Resectable Hepa... | Tislelizumab co... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
